The reduction of HAT1 expression in metastatic melanoma caused the development of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors’ resistance, such as vemurafenib and dabrafenib, kinase inhibitors targeting BRAFV600E in melanoma cells [55]. Here, BRAF is linked to metastatic melanoma.